Recombinant BCG exporting ESAT-6 confers enhanced protection against tuberculosis

Nature Medicine

Volumn 9, Issue 5, 2003, Pages 533-539

  Pym, Alexander S ^a,b   Brodin, Priscille ^a   Majlessi, Laleh ^c   Brosch, Roland ^a   Demangel, Caroline ^a   Williams, Ann ^d   Griffiths, Karen E ^d   Marchal, Gilles ^a   Leclerc, Claude ^c   Cole, Stewart T ^a  

^a INSTITUT PASTEUR   (France)

^b LIVERPOOL SCHOOL OF TROPICAL MEDICINE   (United Kingdom)

^c INSERM   (France)

^d PUBLIC HEALTH ENGLAND   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN; BCG VACCINE; EARLY SECRETORY ANTIGENIC TARGET 6; GENE PRODUCT; PROTEIN CFP 10; PROTEIN ESXA; PROTEIN ESXB; T LYMPHOCYTE ANTIGEN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BACTERIAL VIRULENCE; CONTROLLED STUDY; DISEASE SEVERITY; DNA FLANKING REGION; DRUG POTENCY; FEMALE; GENE DELETION; GENE LOCUS; IMMUNE RESPONSE; IMMUNOGENICITY; MOUSE; MYCOBACTERIUM BOVIS; MYCOBACTERIUM MICROTI; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; TUBERCULOSIS;

ANIMALS; ANTIGENS, BACTERIAL; BACTERIAL PROTEINS; BCG VACCINE; CHROMOSOME MAPPING; FEMALE; GENE DELETION; GUINEA PIGS; MICE; MICE, INBRED C57BL; MYCOBACTERIUM TUBERCULOSIS; PROTEIN TRANSPORT; T-LYMPHOCYTES; TUBERCULOSIS; VACCINATION; VACCINES, SYNTHETIC;

ACTINOBACTERIA (CLASS); ANIMALIA; BACTERIA (MICROORGANISMS); CAVIA; MYCOBACTERIUM; MYCOBACTERIUM BOVIS BCG; MYCOBACTERIUM MICROTI; MYCOBACTERIUM TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS COMPLEX; UNCULTURED ACTINOMYCETE;

EID: 0038751936     PISSN: 10788956     EISSN: None     Source Type: Journal    
DOI: 10.1038/nm859     Document Type: Article

References (45)

1. Fine, P.E.M. Variation in protection by BCG: implications of and for heterologous immunity. Lancet 346, 1339-1345 (1995).
2. Brandt, L. et al. Failure of the Mycobacterium bovis BCG vaccine: some species of environmental mycobacteria block multiplication of BCG and induction of protective immunity to tuberculosis. Infect. Immun. 70, 672-678 (2002).
3. Harboe, M., Oettinger, T., Wiker, H.G., Rosenkrands, I. & Andersen, P. Evidence for occurrence of the ESAT-6 protein in Mycobacterium tuberculosis and virulent Mycobacterium bovis and for its absence in Mycobacterium bovis BCG. Infect. Immun. 64, 16-22 (1996).
4. Behr, M.A. et al. Comparative genomics of BCG vaccines by whole-genome DNA microarrays. Science 284, 1520-1523 (1999).
5. Gordon, S.V. et al. Identification of variable regions in the genomes of tubercle bacilli using bacterial artificial chromosome arrays. Molec. Microbiol. 32, 643-656 (1999).
6. Mahairas, G.G., Sabo, P.J., Hickey, M.J., Singh, D.C. & Stover, C.K. Molecular analysis of genetic differences between Mycobacterium bovis BCG and virulent M. bovis. J. Bacteriol. 178, 1274-1282 (1996).
7. Lewis, K.N. et al. Deletion of RD1 from Mycobacterium tuberculosis mimics bacille Calmette-Guérin attenuation. J. Infect. Dis. 187, 117-123 (2003).
8. Berthet, F.X., Rasmussen, P.B., Rosenkrandt, I., Andersen, P. & Gicquel, B.A. Mycobacterium tuberculosis operon encoding ESAT-6 and a novel low-molecularmass culture filtrate protein (CFP-10). Microbiology 144, 3195-3203 (1998).
9. Colangelli, R. et al. MTSA-10, the product of the Rv3874 gene of Mycobacterium tuberculosis, elicits tuberculosis-specific, delayed-type hypersensitivity in guinea pigs. Infect. Immun. 68, 990-993 (2000).
10. Brandt, L., Oettinger, T., Holm, A. & Anderson, P. Key epitopes on the ESAT-6 antigen recognized in mice during the recall of protective immunity to Mycobacterium tuberculosis. J. Immunol. 157, 3527-3533 (1996).
11. Sorensen, A.L., Nagai, S., Houen, G., Andersen, P. & Andersen, A.B. Purification and characterization of a low-molecular-mass T-cell antigen secreted by Mycobacterium tuberculosis. Infect. Immun. 63, 1710-1717 (1995).
12. SkjØt, R.L.V. et al. Comparative evaluation of low-molecular-mass proteins from Mycobacterium tuberculosis identifies members of the ESAT-6 family as immunodominant T-cell antigens. Infect. Immun. 68, 214-220 (2000).
13. Coler, R.N. et al. Vaccination with the T cell antigen Mtb 8.4 protects against challenge with Mycobacterium tuberculosis. J. Immunol. 166, 6227-6235 (2001).
14. Brandt, L., Elhay, M., Rosenkrands, I., Lindblad, E.B. & Andersen, P. ESAT-6 subunit vaccination against Mycobacterium tuberculosis. Infect. Immun. 68, 791-795 (2000).
15. Brodin, P. et al. Bacterial artificial chromosome-based comparative genomic analysis identifies Mycobacterium microti as a natural ESAT-6 deletion mutant. Infect. Immun. 70, 5568-5578 (2002).
16. Hart, P.D. & Sutherland, I. BCG and vole bacillus vaccines in the prevention of tuberculosis in adolescence and early adult life. Br. Med. J. 2, 293-295 (1977).
17. Sula, L. & Radkovsky, J. Protective effects of M. microtivaccine against tuberculosis. J. Hyg. Epidemiol. Microbiol. Immunol. 20, 1-6 (1976).
18. Cole, S.T. et al. Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence. Nature 393, 537-544 (1998).
19. Tekaia, F. et al. Analysis of the proteome of Mycobacterium tuberculosis in silico. Tubercle Lung Dis. 79, 329-342 (1999).
20. Gey Van Pittius, N.C. et al. The ESAT-6 gene cluster of Mycobacterium tuberculosis and other high G+C Gram-positive bacteria. Genome Biol. 2, 44.1-44.18 (2001).
21. Baldwin, S.L. et al. Evaluation of new vaccines in the mouse and guinea pig model of tuberculosis. Infect. Immun. 66, 2951-2959 (1998).
22. Horwitz, M.A., Lee, B.W., Dillon, B.J. & Harth, G. Protective immunity against tuberculosis induced by vaccination with major extracellular proteins of Mycobacterium tuberculosis. Proc. Natl. Acad. Sci. USA 92, 1530-1534 (1995).
23. Horwitz, M.A., Harth, G., Dillon, B.J. & Maslesa-Galic, S. Recombinant Bacillus Calmette-Guerin (BCG) vaccines expressing the Mycobacterium tuberculosis 30-kDa major secretory protein induce greater protective immunity against tuberculosis than conventional BCG vaccines in a highly susceptible animal model. Proc. Natl. Acad. Sci. USA 97, 13853-13858 (2000).
24. Pallen, M.J. The ESAT-6/WXG100 superfamily - and a new Gram-positive secretion system? Trends Microbiol. 10, 209-212 (2002).
25. Neuwald, A.F., Aravind, L., Spouge, J.L. & Koonin, E.V. AAA+: a class of chaperonelike ATPases associated with the assembly, operation, and disassembly of protein complexes. Genome Res. 9, 27-43 (1999).
26. Renshaw, P.S. et al. Conclusive evidence that the major T-cell antigens of the M. tuberculosis complex ESAT-6 and CFP-10 form a tight, 1:1 complex and characterisation of the structural properties of ESAT-6, CFP-10 and the ESAT-6-CFP-10 complex: implications for pathogenesis and virulence. J. Biol. Chem. 277, 21598-21603 (2002).
27. Page, A.L. & Parsot, C. Chaperones of the type III secretion pathway: jacks of all trades. Mol. Microbiol. 46, 1-11 (2002).
28. Brosch, R. et al. A new evolutionary scenario for the Mycobacterium tuberculosis complex. Proc. Natl. Acad. Sci. USA 99, 3684-3689 (2002).
29. Harboe, M. et al. B-cell epitopes and quantification of the ESAT-6 protein of Mycobacterium tuberculosis. Infect. Immun. 66, 717-723 (1998).
30. Pym, A.S., Brodin, P., Brosch, R., Huerre, M. & Cole, S.T. Loss of RD1 contributed to the attenuation of the live tuberculosis vaccines Mycobacterium bovis BCG and Mycobacterium microti. Mol. Microbiol. 46, 709-717 (2002).
31. Lagranderie, M.R., Balazuc, A.M., Deriaud, E., Leclerc, C.D. & Gheorghiu, M. Comparison of immune responses of mice immunized with five different Mycobacterium bovis BCG vaccine strains. Infect. Immun. 64, 1-9 (1996).
32. Kaufmann, S.H. How can immunology contribute to the control of tuberculosis? Nat. Rev. Immunol. 1, 20-30 (2001).
33. Young, D.B. & Fruth, U. in New Generation Vaccines (eds. Levine, M., Woodrow, G., Kaper, J. & Cobon G.S.) 631-645 (Marcel Dekker, New York, 1997).
34. Jackson, M. et al. Persistence and protective efficacy of a Mycobacterium tuberculosis auxotroph vaccine. Infect. Immun. 67, 2867-2873 (1999).
35. Hondalus, M.K. et al. Attenuation of and protection induced by a leucine auxotroph of Mycobacterium tuberculosis. Infect. Immun. 68, 2888-2898 (2000).
36. Brosch, R. et al. Use of a Mycobacterium tuberculosis H37Rv bacterial artificial chromosome (BAC) library for genome mapping, sequencing and comparative genomics. Infect. Immun. 66, 2221-2229 (1998).
37. Boesen, H., Jensen, B.N., Wilcke, T. & Andersen, P. Human T-cell responses to secreted antigen fractions of Mycobacterium tuberculosis. Infect. Immun. 63, 1491-1497 (1995).
38. Finlay, B.B. & Falkow, S. Common themes in microbial pathogenicity revisited. Microbiol. Mol. Biol. Rev. 61, 136-169 (1997).
39. Garay, S.M. in Tuberculosis (eds. Rom, W.N. & Garay, S.M.) 373-413 (Little, Brown and Company, Boston, 1996).
40. Behr, M.A. & Small, P.M. Has BCG attenuated to impotence? Nature 389, 133-134 (1997).
41. Brandt, L. Key epitopes on the ESAT-6 antigen recognized in mice during the recall of protective immunity to Mycobacterium tuberculosis. J. Immunol. 157, 3527-3533 (1996).
42. Huygen, K. et al. Mapping of TH1 helper T-cell epitopes on major secreted mycobacterial antigen 85A in mice infected with live Mycobacterium bovis BCG. Infect. Immun. 62, 363-370 (1994).
43. Leclerc, C., Deriaud, E., Mimic, V. & Van der Werf, S. Identification of a T-cell epitope adjacent to neutralization antigenic site 1 of poliovirus type 1. J. Virol. 65, 711-718 (1991).
44. Williams, A., Davies, A., Marsh, P.D., Chambers, M.A. & Hewinson, R.G. Comparison of the protective efficacy of bacille Calmette-Guérin vaccination against aerosol challenge with Mycobacterium tuberculosis and Mycobacterium bovis. Clin. Infect. Dis. 30 (suppl. 3), S299-S301 (2000).
45. Chambers, M.A. et al. Identification of a Mycobacterium bovis BCG auxotrophic mutant that protects guinea pigs against M. bovis and hematogenous spread of Mycobacterium tuberculosis without sensitization to tuberculin. Infect. Immun. 68, 7094-7099 (2000).